PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-63.84%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-88.24%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-87.91%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-87.91%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-63.84%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
10Y OCF/share CAGR above 15% – Outstanding long-term cash-generation growth. Warren Buffett would check if reinvestment needs remain manageable.
53.61%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
53.61%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
35.25%
10Y net income/share CAGR above 15% – Exceptional long-term profit growth. Benjamin Graham would confirm if these gains hold through economic cycles.
35.25%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
35.25%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Asset growth above 20% – Rapid expansion. Warren Buffett checks if returns justify this investment and if debt finances it unsafely.
-28.60%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
50.95%
Debt growing over 10% yoy – Potentially high risk. Philip Fisher demands a clear rationale and profitable expansions to offset the debt load.
No Data
No Data available this quarter, please select a different quarter.
47.25%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.